Teva And Celltrion Gain Arthritis Advantage On Rituximab

Truxima Biosimilar Now Available In Rheumatoid Arthritis Indication In US

Teva and Celltrion’s Truxima rituximab biosimilar is now available with a rheumatoid arthritis indication in the US, the firms have revealed, giving it a potential advantage over Pfizer’s Ruxience version.

Watch_Face_Advantage
Teva is aiming to take advantage of its exclusive indication for its rituximab biosimilar • Source: Shutterstock

Teva and Celltrion’s Truxima (rituximab-abbs) biosimilar is now indicated to treat rheumatoid arthritis in the US, the firms have revealed, making it “the only biosimilar to the reference product Rituxan available to treat rheumatoid arthritis in the US.”

At the same time, the companies have also added granulomatosis with polyangiitis and microscopic polyangiitis to the list of indications.

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.